{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(6)"],"submitter":["Lee GP"],"pubmed_abstract":["The dosing intensity of antithymocyte globulin as induction therapy in heart transplantation remains controversial. We sought to evaluate the efficacy and safety of rabbit antithymocyte globulin at a total dose of 4.5 mg/kg compared with <4.5 mg/kg.<h4>Methods</h4>This was a retrospective study of consecutive patients who underwent heart transplantation from January 2016 to December 2018 at a single quaternary care center. Exposure was defined as full antithymocyte globulin (4.5 mg/kg total) induction compared with partial (<4.5 mg/kg) induction. The primary outcome was the incidence of The International Society for Heart and Lung Transplantation 1990 acute cellular rejection grade 2 or above at 2 y. Secondary outcomes were all-cause mortality, number of infections, and time to therapeutic tacrolimus levels. Cox proportional hazard models were used to compare rejection rates and mortality.<h4>Results</h4>Of 201 patients, 61 received partial and 140 received full induction. There was no difference in the cumulative incidence of cellular rejection grade 2 or above (18% versus 11.4%, <i>P</i> = 0.209) within 2 y. The adjusted hazard ratio was 1.45 (confidence interval: 0.62-3.37, <i>P</i> = 0.388) for partial compared with full induction for any grade rejection. Landmark survival analysis conditional on survival to 1 mo showed no difference in mortality (<i>P</i> = 0.239). There was no difference in the incidence of infection within 3 mo of transplant (partial 29.5% versus full 20.0%, <i>P</i> = 0.140). Both groups achieved therapeutic tacrolimus levels by day 7 after initiation.<h4>Conclusions</h4>There was no difference in overall risk for any grade cellular rejection between partial or full dose induction therapy. Additionally, there was no difference in medium-term mortality from landmark survival analysis."],"journal":["Transplantation direct"],"pagination":["e1329"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9148697"],"repository":["biostudies-literature"],"pubmed_title":["Retrospective Evaluation of Rabbit Antithymocyte Globulin Induction in Heart Transplant Patients."],"pmcid":["PMC9148697"],"pubmed_authors":["Lee GP","Fishbein D","Wong B","Wong JM","Wu S","Cheng RK","Vasbinder A","Farris SD"],"additional_accession":[]},"is_claimable":false,"name":"Retrospective Evaluation of Rabbit Antithymocyte Globulin Induction in Heart Transplant Patients.","description":"The dosing intensity of antithymocyte globulin as induction therapy in heart transplantation remains controversial. We sought to evaluate the efficacy and safety of rabbit antithymocyte globulin at a total dose of 4.5 mg/kg compared with <4.5 mg/kg.<h4>Methods</h4>This was a retrospective study of consecutive patients who underwent heart transplantation from January 2016 to December 2018 at a single quaternary care center. Exposure was defined as full antithymocyte globulin (4.5 mg/kg total) induction compared with partial (<4.5 mg/kg) induction. The primary outcome was the incidence of The International Society for Heart and Lung Transplantation 1990 acute cellular rejection grade 2 or above at 2 y. Secondary outcomes were all-cause mortality, number of infections, and time to therapeutic tacrolimus levels. Cox proportional hazard models were used to compare rejection rates and mortality.<h4>Results</h4>Of 201 patients, 61 received partial and 140 received full induction. There was no difference in the cumulative incidence of cellular rejection grade 2 or above (18% versus 11.4%, <i>P</i> = 0.209) within 2 y. The adjusted hazard ratio was 1.45 (confidence interval: 0.62-3.37, <i>P</i> = 0.388) for partial compared with full induction for any grade rejection. Landmark survival analysis conditional on survival to 1 mo showed no difference in mortality (<i>P</i> = 0.239). There was no difference in the incidence of infection within 3 mo of transplant (partial 29.5% versus full 20.0%, <i>P</i> = 0.140). Both groups achieved therapeutic tacrolimus levels by day 7 after initiation.<h4>Conclusions</h4>There was no difference in overall risk for any grade cellular rejection between partial or full dose induction therapy. Additionally, there was no difference in medium-term mortality from landmark survival analysis.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-04T14:40:02.326Z","creation":"2025-02-19T04:57:46.964Z"},"accession":"S-EPMC9148697","cross_references":{"pubmed":["35651585"],"doi":["10.1097/TXD.0000000000001329"]}}